Article

Do changes in femoral neck geometry predict hip osteoarthritis?

A wider femoral neck and more medial centroid position of bone mineral in the femoral neck are associated with an increased risk of prevalent, incident, and progressive radiographic hip osteoarthritis (RHOA). These differences are detectable early in the natural history of hip OA.

A wider femoral neck and more medial centroid position of bone mineral in the femoral neck are associated with an increased risk of prevalent, incident, and progressive radiographic hip osteoarthritis (RHOA). These differences are detectable early in the natural history of hip OA.

Javaid and associates studied 9704 white women 65 years or older in the Study of Osteoporotic Fractures. Common RHOA phenotypes were defined as composite (osteophytes and joint-space narrowing [JSN]), atrophic (JSN, no osteophytes), or osteophytic (femoral osteophytes, no JSN). Pelvic x-ray films were taken at baseline and 8 years later, and hip dual-energy x-ray absorptiometry (DEXA) scans were taken. The Hip Structure Analysis program was applied to the DEXA images to determine bone mineral density and geometry, as well as bone mass, at 3 coronal locations.

Women with a wide femoral neck positioned medially and centroid tended to have osteophytic and composite phenotypes of RHOA but not the atrophic phenotype. Those who had a wide femoral neck positioned centroid also tended to have progression of osteophytes.

The authors noted that qualitative differences in bone remodeling may be critical in the development of specific OA phenotypes and may help identify hips that are at greatest risk for structural progression.
 

Related Videos
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
© 2024 MJH Life Sciences

All rights reserved.